{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:04:27Z","timestamp":1787785467240,"version":"build-2784847793"},"reference-count":62,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019346","name":"Instituto Nacional de Cancerolog\u00eda","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019346","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    B-cell lymphomas are a group of heterogeneic diseases. During B-cell development, the germinal center (GC) reaction is a complex process, in which transcripcional programs have an epigenetic regulation. Enhancer of zeste homologue-2 (EZH2) is a histone methyltransferase, which catalyzes trimethylation of histone H3 at lysine 27 (H3K27me3) to control gene transcription critical for cell proliferation, function, differentiation and expansion. It controls the normal biology of germinal B cells. Epigenetic dysregulation is a hallmark of Diffuse large B- cell lymphoma (DLBCL) and follicular lymphoma (FL), with gain of function (GOF)\n                    <jats:italic>EZH2<\/jats:italic>\n                    mutations. EZH2 is also overexpressed and plays an important role in lymphomagenesis. Follicular lymphoma (FL) pathogenesis includes epigenomic alterations affecting the immunological niche, and their potential consequences on the informational transfer between the microenvironment and tumor B cells. The introduction of novel target therapies and immunotherapeutics modalities in B cell lymphomas has shifted the treatment landscape. Tazemetostat received FDA approval as the first epigenetic therapy for FL. Valemetostat, which inhibits EZH1\/2, as well as tazemetostat in combination with other drugs have been subject of recent research. The purpose of this article is to review the role of EZH2 in normal B cell differentiation and in the pathogenesis of B-Cell lymphomas.\n                  <\/jats:p>","DOI":"10.3389\/fonc.2026.1843273","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T04:50:06Z","timestamp":1778647806000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["The role of EZH2 dysregulation in the pathogenesis of B-cell lymphomas and its implications as a target therapy"],"prefix":"10.3389","volume":"16","author":[{"given":"Myrna","family":"Candelaria","sequence":"first","affiliation":[{"name":"Hospital Angeles Pedregal","place":["Mexico City, Mexico"]},{"name":"Instituto Nacional de Cancerolog\u00eda M\u00e9xico","place":["Mexico City, Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13050861","article-title":"Metabolomics: A new era in the diagnosis or prognosis of B-cell non-Hodgkin\u2019s lymphoma","volume":"13","author":"Alfaifi","year":"2023","journal-title":"Diagnostics (Basell)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/medsci9010005","article-title":"Epidemiology of non-Hodgkin\u2019s lymphoma","volume":"9","author":"Thandra","year":"2021","journal-title":"Med Sci"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26178132","article-title":"Unraveling the epigenetic landscape of mature B cell neoplasia: Mechanisms, biomarkers, and therapeutic opportunities","volume":"26","author":"Maher","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2021.1856652","article-title":"Development of molecular intervention strategies for B-cell lymphoma","volume":"14","author":"Zhou","year":"2021","journal-title":"Exp Rev Hematol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2856","article-title":"Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma","volume":"46","author":"Okosun","year":"2014","journal-title":"Nat Genet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0814-6","article-title":"EZH2 abnormalities in lymphoid Malignancies: underlying mechanisms and therapeutic implications","volume":"12","author":"Li","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-018-0466-6","article-title":"Emerging EZH2 inhibitors and their application in lymphoma","volume":"13","author":"Lue","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-018-0466-6","article-title":"Polycomb genes, miRNA, and their deregulation in B-cell Malignancies","volume":"125","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.1038\/ncomms4127","article-title":"The central role of EED in the orchestration of polycomb group complexes","volume":"5","author":"Cao","year":"2014","journal-title":"Nat Commun"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3960\/jslrt.56.71","article-title":"Molecular pathogenesis of diffuse large B-cell lymphoma","volume":"56","author":"Dobashi","year":"2016","journal-title":"J Clin Exp Hematop"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrfmmm.2008.07.010","article-title":"Roles of the EZH2 histone methyltransferase in cancer epigenetics","volume":"647","author":"Simon","year":"2008","journal-title":"Mutat Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nrm1314","article-title":"The SANT domain: a unique histone-tail-binding module","volume":"5","author":"Boyer","year":"2004","journal-title":"Nat Rev Mol Cell Bio"},{"key":"B13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13148-023-01452-6","article-title":"Clinical advances in epigenetic therapies for lymphoma","volume":"15","author":"Rosenthal","year":"2013","journal-title":"Clin Epigenet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13045-021-01113-2","article-title":"Evolving therapeutic landscape in follicular lymphoma: a look at emerging and investigational therapies","volume":"14","author":"Hanel","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.202000277","article-title":"Treating lymphoma is now a bit EZ-er","volume":"5","author":"Morin","year":"2021","journal-title":"Blood Adv"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2007.01.033","article-title":"The mammalian epigenome","volume":"128","author":"Berstein","year":"2007","journal-title":"Cell"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0510310103","article-title":"A genome-wide analysis of CpG dinucleotides in the human genome distinguishes two distinct classes of promoters","volume":"103","author":"Saxonov","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"B18","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41467-020-20849-y","article-title":"Dynamics of genome architecture and chromatin function during B cell differentiation and neoplastic transformation","volume":"12","author":"Vilarrasa-Blasi","year":"2021","journal-title":"Nat Commun"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/nrg3173","article-title":"Histone methylation: A dynamic mark in health, disease and inheritance","volume":"13","author":"Greer","year":"2012","journal-title":"Nat Rev Genet"},{"key":"B20","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2147\/BLCTT.S282247","article-title":"A promising future for precision epigenetic therapy for follicular and diffuse large B-cell lymphoma","volume":"12","author":"Chung","year":"2022","journal-title":"Blood Lymphat Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1418592112","article-title":"The SWI\/SNF chromatin remodeling complex regulates germinal center formation by repressing Blimp-1 expression","volume":"112","author":"Choi","year":"2015","journal-title":"Proc Natl Acad Sci"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagrm.2022.194828","article-title":"The epigenetic regulation of the germinal center response","volume":"1865","author":"Wu","year":"2022","journal-title":"Biochim Biophis Acta Gene Regul Mech"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.678084","article-title":"Regulatory non-coding RNAs modulate transcriptional activation during B cell development","volume":"12","author":"Attaway","year":"2021","journal-title":"Front Genet"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.09.001","article-title":"Germinal center B cell dynamics","volume":"45","author":"Mesin","year":"2016","journal-title":"Immunity"},{"key":"B25","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1182\/blood-2017-08-737361","article-title":"Chromatin modifying gene mutations in follicular lymphoma","volume":"131","author":"Green","year":"2018","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s12032-023-02025-6","article-title":"The roles of EZH2 in cancer and its inhibitors","volume":"40","author":"Liu","year":"2023","journal-title":"Med Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.cell.2010.10.032","article-title":"Germinal center dynamics revealed by multiphoton microscopy with a photoactivable fluorescente reporter","volume":"143","author":"Victora","year":"2010","journal-title":"Cell"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30145-1","article-title":"Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumors: a first in human, open-label, Phase I study","volume":"19","author":"Italiano","year":"2018","journal-title":"Lancet Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2022.100988","article-title":"Taking EZ way: Targeting enhancer of zeste homolog 2 in B-cell lymphomas","volume":"56","author":"Moschhauser","year":"2022","journal-title":"Blood Rev"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.805195","article-title":"Epigenetic, metabolic, and immune crosstalk in germinal-center-derived B-cell lymphomas: Unveiling new vulnerabilities for rational combination therapies","volume":"9","author":"Serganova","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/sj.emboj.7600414","article-title":"Histone hypomethylatin is an indicator of epigenetci plasticity in quiescent lymphocytes","volume":"23","author":"Baxter","year":"2004","journal-title":"EMBO J"},{"key":"B32","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.ccell.2016.07.006","article-title":"EZH2 and BCL6 cooperate to assemble CBX8-BCOR complex to repress bivalent promoters, mediate germinal center formation and lymphomagenesis","volume":"30","author":"Beguelin","year":"2016","journal-title":"Cancer Cell"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1701470","article-title":"EZH2 represses the B cell transcriptional program and regulates antibody-secreting cell metabolism and antibody production","volume":"200","author":"Guo","year":"2018","journal-title":"J Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2020.08.010","article-title":"Overcoming immune checkpoint blockade resistance via EZH2 inhibition","volume":"41","author":"Kim","year":"2020","journal-title":"Trends Immunol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/leu.2016.175","article-title":"Combined copy number and mutation analysis identifies oncogenic pathways associate with transformation of follicular lymphoma","volume":"31","author":"Bouska","year":"2017","journal-title":"Leukemia"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-021-02234-9","article-title":"The follicular lymphoma epigenome regulates its microenvironment","volume":"41","author":"Amin","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.24875\/RIC.21000070","article-title":"A cohort study of the prognostic impact of exon-16 EZH2 mutations in a Mexican-mestizo population of patients with diffuse large B-cell lymphoma","volume":"73","author":"O\u00f1ate-Oca\u00f1a","year":"2021","journal-title":"Rev Invest Clin"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/ng.518","article-title":"Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin","volume":"42","author":"Morin","year":"2010","journal-title":"Nat Genet"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1177\/20406207231173485","article-title":"Epigenetic targets in B- and T-cell lymphomas: Latest developments","volume":"14","author":"Lima-Ribeiro","year":"2023","journal-title":"Ther Adv Hematol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/nature01075","article-title":"The polycomb group protein EZH2 is involved in progression of prostate cancer","volume":"419","author":"Varambally","year":"2002","journal-title":"Nature"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2012.09.003","article-title":"Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-cell lymphomas","volume":"22","author":"Zhang","year":"2012","journal-title":"Cancer Cell"},{"key":"B42","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s00428-013-1428-y","article-title":"In aggressive variants of non-Hodgkin lymphomas, Ezh2 is strongly expressed and polycomb repressive complex PRC1.4 dominates over PRC1.2","volume":"463","author":"Abd Al Kader","year":"2013","journal-title":"Virchows Arch"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2013.04.011","article-title":"EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation","volume":"23","author":"Beguelin","year":"2013","journal-title":"Cancer Cell"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N Engl J Med"},{"key":"B45","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.ccell.2020.04.004","article-title":"Mutant EZH2 induces a pre-malignant lymphoma niche by reprogramming the immune response","volume":"37","author":"Beguelin","year":"2020","journal-title":"Cancer Cell"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2018-807","article-title":"Mechanism of action of synergistic activity of EZH2 inhibition and IMIDs in preclinical multiple myeloma models [abstract 807","volume":"78","author":"Drew","year":"2018","journal-title":"Cancer Res"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2014.03.001","article-title":"Breaking bad in the germinal center: How deregulation of BCL6 contributes to lymphomagenesis","volume":"20","author":"Hatzi","year":"2014","journal-title":"Trends Mol Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1090","article-title":"Molecular and genetic characterization of MHC deficiency identifies EZH2 as therapeutic target for enhancing immune recognition","volume":"9","author":"Ennishi","year":"2019","journal-title":"Cancer Discov"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.126","article-title":"FAS-antisense 1 lncRNA and production of double versus membrane FAS in B-cell lymphoma","volume":"28","author":"Sehgal","year":"2014","journal-title":"Leukemia"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2019.00986","article-title":"Recent advances in the targeting of epigenetic regulators in B-cell non-Hogdkin lymphoma","volume":"10","author":"Ribeiro","year":"2019","journal-title":"Front Genet"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.06768-11","article-title":"Epigenetic histone modification of Ebstein-Barr virus BZLF1 promoter during latency and reactivation in Raji cells","volume":"86","author":"Murata","year":"2012","journal-title":"J Virol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26104869","article-title":"Liquid biopsy in B and T cell lymphomas: From bench to bedside","volume":"26","author":"Almasri","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14194650","article-title":"ct DNA is useful to detect mutations at codon 641 of exon 16 of EZH2, a biomarker for relapse in patients with diffuse large B-cell lymphoma","volume":"14","author":"D\u00edaz-Chavez","year":"2022","journal-title":"Cancers"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2008.11.004","article-title":"Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms","volume":"32","author":"Margueron","year":"2008","journal-title":"Mol Cell"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-147645","article-title":"MYC stimulates EZH2 expression by repression of its negative regulator miR-26a","volume":"112","author":"Sander","year":"2008","journal-title":"Blood"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.4132\/jptm.2016.06.06","article-title":"Long non-coding RNA HOTAIR expression in diffuse large B-cell lymphoma in relation to polycomb repressive complex pathway proteins and H3K27 trimethylation","volume":"50","author":"Oh","year":"2016","journal-title":"J Pathol Transl Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000000645","article-title":"LncRNA MALAT1 promotes epithelial-to-mesenchymal transition of esophageal cancer through EZh2-Notch1 signaling pathway","volume":"29","author":"Chen","year":"2018","journal-title":"Anticancer Drugs"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004125","article-title":"Epstein Barr virus down-regulates tumor suppressor DOK1 expression","volume":"10","author":"Siouda","year":"2014","journal-title":"PloS Pathog"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1177\/2040620718820510","article-title":"Novel treatment approaches and future perspectives in follicular lymphoma","volume":"10","author":"Sutamtewagul","year":"2019","journal-title":"Ther Adv Hematol"},{"key":"B60","unstructured":"NCCN clinical practice guideline in B-cell lymphoma\n          \n          \n          2026"},{"key":"B61","unstructured":"Clinical trials"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024026131","article-title":"Epigenetic changes by EZH2 inhibition increase translocations in B cells with high AID activity or DNA repair deficiency","volume":"146","author":"Tao","year":"2025","journal-title":"Blood."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1843273\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T04:50:14Z","timestamp":1778647814000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1843273\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":62,"alternative-id":["10.3389\/fonc.2026.1843273"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1843273","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]},"article-number":"1843273"}}